Mavropoulos A, Rigopoulou EI, Liaskos C, Bogdanos DP, Sakkas LI
Patients are required to sign a pharmacy waiver acknowledging this information prior to treatment
Zepbound Data as Reported by Lilly The manufacturers language on the weight loss indication reads thus: Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. At 72 weeks, patients taking Zepbound 15mg lost an average of 20.9% of their body weight
GLP-1 enhances glucose-dependent insulin secretion and suppress plasma glucagon release , helping to maintain stable blood glucose levels
Side effects range from nausea, vomiting and diarrhea to more serious complications such as pancreatitis, acute kidney injury and intestinal paralysis
From your first provider reviewed intake to your Semaglutide or Tirzepatide delivery by one of our U.S